Photo for representation
Tokyo, November 23
Remdesivir could reduce mortality in patients if given within nine days of the onset of covid symptoms, according to a study in Asian patients.
Researchers at Tokyo Medical and Dental University (TMDU) found that treatment with remdesivir within nine days of the onset of covid symptoms reduced mortality in Asian patients also taking corticosteroids, according to the study.
Several studies, according to the study, have already shown that remdesivir can shorten recovery time in covid patients, although there are conflicting reports on whether the drug prevents patients from dying. In addition, previous trials did not focus on people who needed help breathing. stay in intensive care.
“Given the inconsistent evidence related to the survival advantages it confers, we sought to investigate the effectiveness of remdesivir in covid patients, who were admitted to an intensive care unit in Japan,” said Mariko Hanafusa, first of the study.
“All of those patients were being treated with corticosteroids for pneumonia, and some were receiving breathing mechanics,” Hanafusa said.
According to the study, researchers analyzed the medical records of 168 covid patients admitted to intensive care at TMDU Hospital between April 2020 and November 2021. The patients were divided into teams based on whether they also received treatment with remdesivir, according to the study, published in the journal. Journal of Medical Virology, he said.
“The effects showed a transparent difference in patients’ survival depending on when they won remdesivir treatment,” said study leader Takeo Fujiwara.
The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).